BIIB

Nasdaq

BIOGEN INC.

Health Care, Biotechnology

$207.94

close 7 Aug 2026

+62.45%

52-week change

$30.70B

market cap

$127.71

$219.72

52-week range

Expected price

$139.06 – $169.96

Current price

$207.94

Signal

Could be overvalued

A historical-multiple reference, never a fair-value claim. The band uses only data public at each date and ends at the latest month — no forward estimates.

Current multiples

P/E (TTM)22.36x

P/S (TTM)3.09x

P/B1.65x

EV/EBITDA (TTM)12.77x

FCF yield (TTM)7.89%

PEG (TTM, GAAP)—

Context

P/E, own 5-year average18.51x

P/E, sector median29.65x*

Price at 5-year median P/E$169.01*

Forward — analyst consensus

Forward P/E (FY2026)16.70x*

Forward P/E (FY2027)12.53x

Forward PEG0.50*

Consensus EPS FY2026 (29 analysts)$12.45

EPS growth (FY2026→FY2027)33.24%

Revenue growth (FY2026)5.37%

Street view

Price target (mean)$235.32*

Target upside13.17%

Ratings (buy / hold / sell)23 / 12 / 1

FY2026 EPS revisions, 30d (up / down)0 / 20

5-year history

Dashed line: average of month-end values

P/E (TTM)

P/S (TTM)

P/B

FCF yield (TTM)

period to 31 Mar 2026, filed 29 Apr 2026, close 7 Aug 2026

Discounted cash flow

Ten projected years plus a perpetuity, prefilled from filings — a model to argue with, never a fair-value claim.

Free cash flow, last ten years and TTM

5Y CAGR -11.63%10Y CAGR -4.58%

Assumptions

Growth rate, years 1–10%

Perpetual growth%Discount rate%

Base FCF$M

As filed — not assumptions

Current price$207.94

Cash & equivalents$2.51B

Total debt$6.29B

Shares outstanding147.64M

Result

DCF price per share$79.51

Current price$207.94

Margin of safety-61.76%

PV of years 1–10$9.44B

PV of terminal value$6.07B

Equity value$11.74B

Market-implied growth-0.97%

Projected FCF, years 1–10

Hover for PV and growth

Projection detail

Override growth for any year; blank years use the uniform rate

Year	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	Terminal
Growth, %											2.5
FCF	$2.14B	$1.89B	$1.67B	$1.48B	$1.31B	$1.15B	$1.02B	$901.10M	$796.30M	$703.69M	$13.11B
PV	$1.98B	$1.62B	$1.33B	$1.09B	$888.67M	$727.15M	$594.98M	$486.84M	$398.35M	$325.95M	$6.07B

period to 31 Mar 2026, filed 29 Apr 2026, close 7 Aug 2026